Let us be the generation who stands up to cytomegalovirus (CMV), a highly contagious viral infection that can harm an unborn child. Currently, there is no approved vaccine against this devastating virus. The CMVictory Trial is studying an investigational vaccine to protect against CMV infection.
Globally, about 1 in 150 infants are born with CMV1
CMV is a leading cause of birth defects around the world2
This clinical trial is looking for participants.
To join, you must be:
- Female ages 18 to 40
- Not pregnant or planning on becoming pregnant in the 9 months following your vaccine visit
- If you are age 20 or older: Expecting to or currently have close contact with a child 5 years of age or younger for at least 8 hours a week
References:
1. Ssentongo P, Hehnly C, Birungi P, et al. Congenital cytomegalovirus infection burden and epidemiologic risk factors in countries with universal screening: a systematic review and meta-analysis. JAMA Netw Open.2021;4(8):e2120736. doi:10.1001/jamanetworkopen.2021.207362. Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK. The“silent” global burden of congenital cytomegalovirus. Clin Microbiol Rev.2013;26(1):86-102.doi:10.1128/CMR.00062-12
